

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (review of TA132)

Provisional Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Merck Sharp & Dohme (ezetimibe) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Blood Pressure UK • British Cardiac Patients Association • British Hypertension Society • Cardiovascular Care Partnership • Coronary Prevention Group • Equalities National Council • HEART UK • Muslim Council of Britain • Muslim Health Network • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • British Association for Nursing in Cardiovascular Care • British Atherosclerosis Society • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Nuclear Cardiology Society • British Society of Cardiac Radiology • College of Emergency Medicine • Faculty of Public Health Medicine • National Obesity Forum • Nurses Hypertension Association • Obesity Management Association • Royal College of General Practitioners • Royal College of Nursing 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Accord (pravastatin, simvastatin) • Actavis UK (atorvastatin, simvastatin, fluvastatin) • AstraZeneca (rosuvastatin) • Aurobindo Pharma-Milpharm (pravastatin, simvastatin) • Bristol Myers Squibb (pravastatin) • Consilient Health (atorvastatin) • Dexcel Pharma (atorvastatin, simvastatin) • Discovery (simvastatin) • Kent Pharmaceuticals (simvastatin) • Merck Sharp & Dohme (simvastatin) • Novartis (fluvastatin) • Pfizer (atorvastatin) • Rosemont Pharmaceuticals (simvastatin) • Sandoz (fluvastatin, simvastatin,) • Zentiva UK (atorvastatin, simvastatin,

Appendix B – Provisional matrix

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society for Vascular Technology of Great Britain and Ireland • Society of Vascular Nurses • The Somerville Foundation • UK Health Forum • United Kingdom Clinical Pharmacy Association • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Oxfordshire CCG • NHS West Essex CCG • Welsh Government 	<p>fluvastatin)</p> <ul style="list-style-type: none"> • Wockhardt UK (atorvastatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Antithrombotic Trialists' (ATT) Collaboration • British Society for Cardiovascular Research • Central Cardiac Audit Database • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane Peripheral Vascular Diseases Group • Cochrane Stroke Group • CODA • Health Research Authority • MRC Clinical Trials Unit • National Heart Research Fund • National Institute for Health Research • Wellcome Trust - Cardiovascular Research Initiative <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • NHS Centre for Reviews & Dissemination and Centre for Health Economics –York • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre • Scottish Intercollegiate Guidelines Network <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales NHS Trust

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.